Phase3 Study of TS-071 in Patients With Type 2 Diabetes Mellitus (Double-blind, Parallel Group,Placebo-Controlled Study)
Phase 3
- Conditions
- Type 2 Diabetes Mellitus
- Registration Number
- JPRN-jRCT2080221620
- Lead Sponsor
- Taisho Pharmaceutical co., LTD
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 132
Inclusion Criteria
Type 2 diabetes mellitus
- HbA1c 6.5% to 10.0%
etc.
Exclusion Criteria
- Except type 2 diabetes mellitus.
- Having critical Heart Disease, other ciruculatory disease, cerebrovascular disorder, pancreatic disease and hematologic disease.
etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HbA1c
- Secondary Outcome Measures
Name Time Method Blood-sugar level, etc.